Table of Contents Author Guidelines Submit a Manuscript
Canadian Journal of Gastroenterology
Volume 22, Issue 10, Pages 821-824
Original Article

Liver Transplantation for Hepatic Epithelioid Hemangioendothelioma: The Canadian Multicentre Experience

Carmine G Nudo,1 Eric M Yoshida,2 Vincent G Bain,3 Denis Marleau,4 Phil Wong,5 Paul J Marotta,6 Eberhard Renner,7 Kymberly D Watt,8 and Marc Deschênes1

1McGill University, Montréal, Québec, Canada
2University of British Columbia, Vancouver, British Columbia, Canada
3University of Alberta, Edmonton, Alberta, Canada
4Université de Montréal, Montréal, Québec, Canada
5University of Toronto, Toronto, Ontario, Canada
6University of Western Ontario, London, Ontario, Canada
7University of Manitoba, Winnipeg, Manitoba, Canada
8Dalhousie University, Halifax, Nova Scotia, Canada

Received 11 December 2007; Accepted 27 May 2008

Copyright © 2008 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


INTRODUCTION: Hepatic epithelioid hemangioendothelioma (HEHE) is a rare entity. At the present time, there is no standardized effective therapy. Liver transplantation (LT) has emerged as a treatment for this rare tumour.

OBJECTIVE: To evaluate the outcome of liver transplantation for HEHE at eight centres across Canada.

METHODS: The charts of patients who were transplanted for HEHE at eight centres across Canada were reviewed.

RESULTS: A total of 11 individuals (eight women and three men) received a LT for HEHE. All LTs were performed between 1991 and 2005. The mean (± SD) age at LT was 38.7±13 years. One patient had one large liver lesion (17 cm × 14 cm × 13 cm), one had three lesions, one had four lesions and eight had extensive (five or more) liver lesions. One patient had spleen involvement and two had involved lymph nodes at the time of transplantation. The mean duration of follow-up was 78±63 months (median 81 months). Four patients (36.4%) developed recurrence of HEHE with a mean time to recurrence of 25±25 months (median 15.6 months) following LT. The calculated survival rate following LT for HEHE was 82% at five years.

CONCLUSIONS: The results of LT for HEHE are encouraging, with a recurrence rate of 36.4% and a five-year survival rate of 82%. Further studies are needed to help identify patients who would benefit most from LT for this rare tumour.